This is rather large. The fact that Monsanto did it right in front of a trial, they (the university) must have had a lock-shut case.

418

That would make for a much quicker response to a flu outbreak, and would help move vaccine technology into the 21st century. Right now vaccine technology is in the middle of the 20th century. It just doesn't make sense to rely on outdated methods that have been around 40 years.

285

Diversify risk by buying different size companies or those at different stages of development, ... Selectively choose from larger biotech names and those with later-stage development drugs which might become high fliers or losers.

264

A major wild card that has yet to really surface is legislation that allows U.S. corporations to repatriate foreign earnings at a 5.25 percent tax rate instead of 35 percent. To be eligible the money has to be repatriated in 2005 and reinvested by Dec. 31, 2007. While the money cannot be used for many corporate activities, it can be used for mergers and acquisition.

217

The Swiss are much smarter than American pharmaceutical firms.

160

The FDA will be asking the toughest questions you can imagine and the investment community will be on pins and needles to find out what the agency wants.

123

They definitely had sex appeal and make a good story, but they didn't make any money. When the rubber hits the road, if you're not delivering it is hard to go out and get investors.

121